Antitumor activity of 4-amino and 8-methyl-4-(3diethylamino propylamino)pyrimido[4′, 5′:4, 5]thieno (2, 3-b) quinolines

Journal of Photochemistry and Photobiology B: Biology

Volumn 72, Issue 1-3, 2003, Pages 69-78

  Gopal, Muttagi ^a   Shenoy, S ^b   Doddamani, L S ^c  

^a KUVEMPU UNIVERSITY   (India)

^b RELIANCE LIFE SCIENCES PVT LTD   (India)

^c KARNATAK UNIVERSITY   (India)

Author keywords

Antitumor activity; DNA; Fluorescence quenching; Intercalative binding; Pyrimidothienoquinoline

Indexed keywords

2 METHYLELLIPTICINE; 4 AMINOPYRIMIDO[4',5':4,5]THIENO(2,3 B)QUINOLINE; 8 METHYL 4 (3 DIETHYLAMINOPROPYLAMINO)PYRIMIDO[4',5':4,5]THIENO(2,3 B)QUINOLINE; 9 HYDROXYELLIPTICINE; ANTINEOPLASTIC AGENT; CYTOSINE; DNA; GUANINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ABSORPTION SPECTROSCOPY; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER GRAFT; CELL STRAIN HL 60; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DESIGN; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC 50; IONIC STRENGTH; LEUKEMIA CELL; MELANOMA B16; MICROCOCCUS LUTEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECTROFLUOROMETRY; TUMOR GROWTH; ULTRAVIOLET SPECTROPHOTOMETRY;

MICROCOCCUS; MICROCOCCUS LUTEUS;

EID: 0344237179     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2003.09.003     Document Type: Article

References (39)

1. V.K. Kansal, P. Potier, The biogentic, synthesis and biochemical aspects of ellipticine antitumor alkaloids, Tetrahedron 42 (1986) 2389-2408.
2. P. Jurnet, A. Tanguy, A. Giraad, J.Y. LeTalaer, J.S. Abbatucci, N.G. Dat xuong, J.B. Le Pecq, C. Paoletti, Priliminary trail of 9-hydroxy-2-methyl-ellipticinium (NSC 246,137) in advanced human cancer, Eur. J. Cancer 14 (1978) 205-211.
3. G. Mathe, M. Hayath, F. deVassal, L. Schwartzenberg, M. Schneider, R. Schlumberger, C. Jasmin, C. Kosenfeld, Methoxy-9-ellipticine lactate III. Clinical screening: its action in acute myeloblastic leukemia, Rev. Eur. Etnd. Clin. Biol. 15 (1970) 541-549.
4. L. Larue, C. Rivalle, G. Muzard, C. Paoletti, E. Bissangi, J. Paoletti, A New series of ellipticine derivatives (1-(alkylamino)-9-methoxyellipticine): synthesis, DNA binding and biological properties, J. Med. Chem. 31 (1970) 1951-1958.
5. C. Auclair, A. Pierre, E. Voisin, O. Pepin, S. Cros, C. Colas, J.M. Scancier, B. Verschur, P. Gros, C. Paoletti, Physiochemical and pharmacological properties of antitumor ellipticine derivative 2-(diethylamino-2-ethyl) 9-hydroxyellipticinumchloride, HCI, Cancer Res. 47 (1987) 6254-6262.
6. J.B. Le Pecq, C.H. Gosse, C. Paoletti, D. Chalrat, N.G. Dat-Xuong, in: E. Bergmann, E. Pulmann (Eds.), Molecular and quantum pharmacology, 1974, pp. 515-535.
7. C. Auclair, E. Voisin, J. Banoun, C. Paoletti, J. Bernadou, B. Meunier, Potential antitumor agents: synthesis and properties of alliphatic aminoacid 9-hydroxy ellipti cinium derivatives, J. Med. Chem. 27 (1984) 1161-1166.
8. M. Sainsbury, The synthsis of 6 H-pyrido[4,3-b] carbazoles, Synthesis 7 (1977) 437-448.
9. Y. Takeuchi, T. Oda, M.R. Chang, Y. Okamoto, J. Ono, Y. Oda, K. Harada, K. Hashigaki, M. Yamoto, Synthesis and antitumor activity of fused quinoline derivatives. IV. Novel 11-aminoindolo (2,3-b)quinolines, Chem. Pharm. Bull. (Tokyo) 45 (1997) 406-411.
10. B. Allard, M. Jouini, G.A. Bistocchi, P.L. Orvietani, A. Ricci, E. Lescot, A. Schwaller, Isomeric ellipticine part 2: acid-base properties and interaction with DNA of four linear isomers of antitumor drug and deoxyribonucleic acid, J. Chem. Res. (S) (1995) 218-219.
11. A. Baez, F.A. Gonzalez, D. Vazquez, M. Waring, Interaction between a 3-nitrobenzothioazole(3,2-a) quinolinium antitumor drug and deoxyribonucleic acid, Biochem. Pharma. 32 (1983) 2089-2094.
12. T. Tilak Raj, S.Y. Ambekar, Synthesis of 4-amino pyrimido [4′, 5′:4,5] thieno (2,3-b) quinolines, J. Chem. Eng. Data 33 (1988) 530-531.
13. T. Tilak Raj, S.Y. Ambekar, Synthesis of 4-amino pyrimido [4′, 5′:4,5] thieno (2,3b) quinoline-4(3H)-ones, J. Chem. Res. (S) 50 (1988) 537-551.
14. M. Gopal, M.S. Shahabuddin, S. Inamdar, Interaction between a 8-methoxy pyrimido [4′, 5′:4,5] thieno (2,3-b)quinoline-4(3H -one antitumor drug and deoxyribonucleic acid, Proc. Indian Acad. Sci. (Chem. Sci.) 114 (2002) 687-696.
15. C. Auclair, Multimodal action of antitumor agents on DNA: the ellipticine series, Arch. Biochem. Biophys. 259 (1987) 1-14.
16. G. Schatchard, The attraction of proteins for small molecules and ions, Ann. N.Y. Acad. Sci. 51 (1949) 660-672.
17. W. Muller, D.M. Crothers, Studies of binding of Actinomycin and related compounds to DNA, J. Mol. Biol. 35 (1968) 251-290.
18. J.D. McGhee, D.H. von-Hipple, Theoretical aspects of DNA protein interactions: co-operative and non co-operative binding of large ligands to a one-dimensional homogeneous lattice, J. Mol. Biol. 86 (1974) 469-489.
19. J.M. Saucier, B. Festy, J.B. Le Pecq, The change of the torsion of the DNA helix caused by intercalation II-Measurement of the relative change of torsion induced by various intercalating drugs, Biochimie 53 (1971) 973-980.
20. Y. Cao, Xi-Wan He, Studies of interaction between Safranine T and double helix DNA by spectral methods, Spectachim. Acta Part A 54 (1998) 883-892.
21. F. Danizot, R. Lang, Rapid colorimetric assay for cell growth and survival identification to the tetrazolium dye procedure giving improved sensitivity and reliability, J. Immunol. Methods 89 (1986) 271-274.
22. H.R. Hendriks, S. Langdon, D.P. Berger, K. Breistol, H.H. Fiebig, Fodstand, G. Schwartsmann, Comparitive antitumor activity of vinblastin isoleucinate and related vinka alkaloids in human tumor Xenografts, Eur. J. Cancer 28A (1992) 767-772.
23. J. Plowmann, D.J. Dykes, Hollingshied, L. Simpson-Herren, M.C. Allaey, in: B.A. Teicher (Ed.), Anticancer Drug Development Guide, Humana Press, Totowa, NJ, 1997, pp. 101-125.
24. A. Kruczynski, F. Colpaert, J.P. Taire, P. Mouillard, J. Fahy, B.T. Hill, Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinka alkaloid, Cancer. Chemother. Pharmacol. 41 (1998) 437-478.
25. Q.G. Li, H.M. Wang, A.Z. Li, Molecular Biophysical Chemistry Chinese, Higher education publisher, Beijing, 1992, pp. 276-328.
26. C. Ducrocq, F. Wendling, M. Tourbez-Perrin, C. Rivalle, P. Tambourin, F. Pocon, E. Bisagni, J.C. Chermann, Structure-activity relationships in a series of newly synthe sized amino substituted ellipticine derivatives, J. Med. Chem. 23 (1980) 1212-1216.
27. M.J. Waring, in: G.C.K. Roberts (Ed.), Drug Action at the Molecular Level, MacMillan, London, 1977, p. 167.
28. G.L. Zuby, Biochemistry, second ed., MacMillan, New York, 1988, p. 236.
29. S.P. Langdon, H.R. Hendriks, G. Pratesi, D.P. Berger, Fodstand, H.H. Fiebig, E. Boven, Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study, Ann. Oncol. 5 (1994) 415-422.
30. W. Muller, D.M. Crothers, Studies of the binding of Actinomycin and related compounds to DNA, J. Mol. Biol. 35 (1968) 251 257.
31. J.W. Lown, The chemistry of DNA damage by antitumor drugs, in: S. Niedle, M.J. Waring (Eds.), Molecular Aspects of Anticancer Drugs Action, Weinheim, Verlag, 1983, pp. 283-314.
32. J.B. Chaires, N. Dattagupta, D.M. Crothers, Studies on interaction of anthracycline antibiotics and DNA: equilibrium binding studies on interaction of daunomycin with DNA, Biochem. 21 (1982) 3933-3940.
33. A. Schwaller, J. Aubard, C. Auclair, C. Paoletti, G. Dodin, Kinetic and thermodynamic studies on drug-DNA interaction in the ellipticine series, Anticancer Drug-Des. 5 (1990) 77-87.
34. M.J. Waring, Variation of the supercoils in closed circular DNA by binding of antibiotics: evidence for molecular models involving intercalation, J. Mol. Biol. 54 (1970) 247-279.
35. E. Frei, C.A. Bieler, V.M. Arlt, M. Wiessler, M. Stiborova, Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes, Biochem. Pharmacol. 64 (2002) 289-295.
36. M. Stiborova, C.A. Bieler, M. Wiessler, E. Frei, The anticancer agent ellipticine upon activation by cytochrome P450 forms covalent DNA adducts, Biochem. Pharmacol. 62 (2001) 1675-1684.
37. M.C. Bissery, D. Guenad, F. Gueritte-Voegelein, Exprimental antitumor activity of taxotere (RP56976, NSc 628503), a taxol analogue, Cancer Res. 51 (1991) 4845-4852.
38. C. Paoletti, S. Cros, N. Dat-Xuong, P. Lecointe, A. Moisand, Comparative cytotoxic and antitumoral effect of ellipticine derivatives on mouse L1210 leukemia, Chem. Biol. Interactions 25 (1979) 45-58.
39. V. Moinet-Hendis, T. Tabaka, L. Poulain, T. Godard, M. Saturnino, J.C. Lancelot, J.Y. Le Talaer, P. Gaudunchon, Biological properties of 5,10-dimethyl-6H-pyrido (3,2-b)carbazoles: a new class of potent antitumor drugs, Anticancer Drug Des. 15 (2000) 109-118.